Phage therapy program
SASPiPhi Limited / STEPS-CF
| Status | Research/development |
|---|---|
| Type | Company |
| Location | Cambridge (sponsor); Liverpool (planned trial); United Kingdom |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | New ISRCTN trial registration identifies sponsor SASPiPhi Limited and the NIHR Liverpool Clinical Research Facility at Royal Liverpool University Hospital; recruitment has not begun. |
|---|---|
| Areas of work | Phase 1b/2a IV engineered SASPject PT3.9 for adults aged 18–60 with CF-associated susceptible P. aeruginosa infection; projected first enrollment January 1, 2027. |
| International access | Planned England trial; international eligibility was not established. |
What to confirm
- Trial registration and future enrollment dates do not establish current patient access.
- Registry target 64 differs from the summary cohort arithmetic; the registry target is preserved without resolving it.
- Do not assume legal continuity with Phico Therapeutics without further evidence.
Related studies(1)
STEPS-CF / SASPject PT3.9
Not yet recruiting
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | eu-saspiphi-steps-cf |
|---|